Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
The Growth Hormone Secretagogues and Epilepsia
share announcement

The Growth Hormone Secretagogues and Epilepsia

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: closed (25 July 2022) | Viewed by 2455

Special Issue Editors

Dr. Antonio Torsello

E-Mail Website
Guest Editor
School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Interests: neuropeptides; epilepsy; GHS; neurodegenerative diseases
Dr. Robert J. Omeljaniuk

E-Mail Website
Guest Editor
Department of Biology, Lakehead University, Thunder Bay, ON, Canada
Interests: endocrinology; neuroendocrinology; neuropsychopharmacology; neuroimmunoendocrinology

Special Issue Information

Dear Colleagues,

This Special Issue of the Journal of Personalized Medicine welcomes manuscripts focusing on the most recent advances in mechanisms involved in epileptogenesis, as well as on the possible innovative treatments. In recent years, the neuropeptide ghrelin and its synthetic analogues (GHSs) have emerged as promising candidates in the field of epilepsy. Human studies have shown increased or decreased levels of ghrelin in patients with epilepsy. The effects of ghrelin are usually suggested to be mediated by its action on the GHSR1a, but some studies have already indicated the possibility that ghrelin’s neuroprotective effects could be independent of the GHSR1a. The GHSs have great clinical potential in the field of epilepsy, and a better understanding of their mechanism of anticonvulsant action could promote the development of novel synthetic analogs with clinical potential in epilepsy.

Dr. Antonio Torsello
Dr. Robert J. Omeljaniuk
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ghrelin
  • hexarelin
  • GHS
  • epilepsy
  • translational research
  • prevention and treatment
  • personalized medicine
  • clinical studies 
  • preclinical models

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1314 KiB  
Article
Prospective Evaluation of Ghrelin and Des-Acyl Ghrelin Plasma Levels in Children with Newly Diagnosed Epilepsy: Evidence for Reduced Ghrelin-to-Des-Acyl Ghrelin Ratio in Generalized Epilepsies
by Anna-Maria Costa, Tommaso Lo Barco, Elisabetta Spezia, Valerio Conti, Laura Roli, Lorenza Marini, Sara Minghetti, Elisa Caramaschi, Laura Pietrangelo, Luca Pecoraro, Fabio D’Achille, Paola Accorsi, Tommaso Trenti, Federico Melani, Carla Marini, Renzo Guerrini, Francesca Darra, Patrizia Bergonzini and Giuseppe Biagini
J. Pers. Med. 2022, 12(4), 527; https://doi.org/10.3390/jpm12040527 - 25 Mar 2022
Cited by 8 | Viewed by 2094
Abstract
Children with epilepsy and identified as responders to antiseizure medications (ASMs) were found to present markedly higher ghrelin plasma levels when compared to drug-resistant patients. However, it was undetermined if this phenotype could be influenced by the ASMs. Here, we prospectively investigated total [...] Read more.
Children with epilepsy and identified as responders to antiseizure medications (ASMs) were found to present markedly higher ghrelin plasma levels when compared to drug-resistant patients. However, it was undetermined if this phenotype could be influenced by the ASMs. Here, we prospectively investigated total ghrelin and des-acyl ghrelin (DAG) plasma levels by enzyme-linked immunosorbent assay before and after ASM administration. Inclusion criteria were: (i) subject with a suspicion of epilepsy; (ii) age ranging from 0 to 16 years; and (iii) informed consent signed by parents or caregivers. Exclusion criteria were acute or chronic metabolic disorders with occasional convulsions but without epilepsy. Fifty patients were followed over a period of one year in Italian neuropediatric centers. Apart from a few exceptions, the majority of children were responsive to ASMs. No differences were found in total ghrelin and DAG levels before and after the treatment, but total ghrelin levels were significantly lower in children with generalized epilepsy compared to those with combined focal and generalized epilepsy. Moreover, the ghrelin-to-DAG ratio was also markedly lower in generalized epilepsies compared to all the other types of epilepsy. Finally, ghrelin was unchanged by ASMs, including the first (e.g., carbamazepine), second (levetiracetam), and third (lacosamide) generation of anticonvulsants. Full article
(This article belongs to the Special Issue The Growth Hormone Secretagogues and Epilepsia)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop